Vertex Pharmaceuticals stock is a "Strong Buy", driven by robust CF franchise growth and successful label expansions for ...

Vertex Pharmaceuticals (VRTX) stock is in focus as the FDA greenlights label expansions for its cystic fibrosis drugs, ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved ...

A medical research ecosystem that helped produce inspiring advances is in jeopardy, writes the Register's editorial board.

As of February 13, 2026, Sionna Therapeutics shares were priced at $34.99, up about 144% over the past year and far surpassing the S&P 500’s roughly 19% gain in the same period. Sionna Therapeutics ...

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/ivacaftor) for the treatment of ...

Patients aged 6 years and older with cystic fibrosis will be able to access the triple combination treatment vanzacaftor/tezacaftor/deutivacaftor on NHS Scotland ...

Modulator pills transformed cystic fibrosis care. But the fight for a cure is not over — so long as research remains funded.

VRTX stock slips nearly 5% as concerns over new drug uptake and pipeline setbacks weigh, even as its dominant CF franchise continues to drive steady growth.

A new product approval may be right around the corner.

A decade of war in Ukraine has led to widespread PTSD, depression, and suicidal behavior in children, need for perceived ...